Has John Epling received payments from drug or device companies?

Yes. Drug and device makers reported $27,768 in general payments to John Epling across 736 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Epling did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Epling come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Epling

Endocrinology, Diabetes & Metabolism · Bridgeport, WVNPI 1811332166

Payments from drug & device makers

$27,768in general payments, 2019–2025

Across 736 payments — averaging $37.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$10K
Dexcom, Inc.$7K
Medtronic$2K
AstraZeneca$1K
Lilly USA, LLC$1K
Amgen$1K
plus $6K from 37 others

What the payments were for

Consulting fees$7,15526%
Speaking & faculty fees$4,89618%
Travel & lodging$2,66410%
Food & beverage$13,02947%
Education$240%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	174	$9,815
Dexcom, Inc.	66	$6,996
Medtronic(2 entities)	19	$1,654
AstraZeneca(2 entities)	69	$1,144
Lilly USA, LLC	58	$1,047
Amgen(2 entities)	47	$1,033
Sanofi-aventis U.S. LLC	55	$922
Tandem Diabetes Care, Inc.	14	$858
Abbott	44	$850
Boehringer Ingelheim	36	$601
AbbVie	23	$405
Insulet Corporation	22	$400
Phathom Pharmaceuticals, Inc.	2	$230
Bayer	12	$220
Merck	15	$196
Amarin Pharma, Inc.	13	$163
Mannkind Corporation	10	$157
Zealand Pharma US, Inc.	7	$120
Xeris Pharmaceuticals, Inc.	6	$101
Johnson & Johnson	5	$95
IBSA Pharma Inc.	5	$82
Pfizer	4	$78
Rhythm Pharmaceuticals, Inc.	3	$70
Nestle Healthcare Nutrition Inc.	2	$67
Nevro Corp.	3	$54
GRT US Holding, Inc.	2	$40
Esperion Therapeutics, Inc.	2	$39
Ultragenyx Pharmaceutical Inc.	2	$38
Shire North American Group Inc	2	$32
Amryt Pharma Holdings Ltd	1	$25
Recor Medical Inc	1	$25
Ascensia Diabetes Care US Inc.	1	$24
Astellas Pharma US Inc	1	$21
Novartis	1	$20
BD	1	$19
Mylan Specialty L.p.	1	$19
Ipsen Biopharmaceuticals, Inc	1	$18
Averitas Pharma Inc.	1	$17
Boston Scientific	1	$16
EUSA Pharma (US) LLC	1	$16
Recordati_rare_diseases_inc.	1	$16
Corcept Therapeutics	1	$16
AMAG Pharmaceuticals, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,768 in reported general payments places this provider in the 90th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.

See all endocrinology, diabetes & metabolism providers in West Virginia →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	739	$1,121,743
OzempicSemaglutide	256	$371,056
JardianceEmpagliflozin	133	$172,637
Tresiba Flextouch U-200Insulin Degludec	76	$88,351
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	58	$60,663
FarxigaDapagliflozin Propanediol	55	$56,175
TrulicityDulaglutide	34	$40,169
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	23	$35,723
Cinacalcet Hcl	78	$29,598
Tresiba Flextouch U-100Insulin Degludec	41	$29,037
TradjentaLinagliptin	22	$23,809
Novolog FlexpenInsulin Aspart	76	$22,407
Soliqua 100-33Insulin Glargine/Lixisenatide	20	$19,496
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	97	$18,903
Gvoke Hypopen 2-PackGlucagon	32	$18,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro	$1,047	$1,163,755788 claims
Novo NordiskOzempic, Novolog, Fiasp	$9,815	$403,849316 claims
Boehringer IngelheimJardiance, Tradjenta	$601	$196,445155 claims
AstraZenecaFarxiga	$1,144	$56,17555 claims
Sanofi-aventis U.S. LLCSoliqua 100-33	$922	$19,49620 claims
AbbVieSynthroid, Armour Thyroid	$405	$11,183123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.

Other endocrinology, diabetes & metabolism in Bridgeport

Jeremy SouleBridgeport$120K
Timothy JacksonBridgeport$7K
Ayman ElkadryHuntington$767K
Daniel MaciasHuntington$686K
Zachary KistkaMartinsburg$120K
Philip RyanMartinsburg$35K
Greta GuyerSouth Charleston$22K
Arlene FederWeirton$20K
Ziad KahwashSouth Charleston$17K
Adnan HaiderMorgantown$13K

See the full list for West Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →